$1.58
1.94%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US75989R1077
Symbol
RNXT

RenovoRx Inc Target price 2026 - Analyst rating & recommendation

RenovoRx Inc Classifications & Recommendation

Buy
90%
Hold
10%

RenovoRx Inc Price Target

Target Price $5.61
Price $1.55
Potential
Number of Estimates 6
6 Analysts have issued a price target RenovoRx Inc 2027 . The average RenovoRx Inc target price is $5.61. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend RenovoRx Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the RenovoRx Inc stock has an average upside potential 2027 of . Most analysts recommend the RenovoRx Inc stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 1.12 3.95
2,700.00% 252.68%
Net Margin -997.32% -305.85%
95.47% 69.33%

6 Analysts have issued a sales forecast RenovoRx Inc 2026 . The average RenovoRx Inc sales estimate is

$4.0m
unlock
. This is
99.49% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.2m 114.39%
unlock
, the lowest is
$3.6m 81.77%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $1.1m 2,700.00%
2026
$4.0m 252.68%
unlock
2027
$11.7m 195.24%
unlock
2028
$34.2m 193.25%
unlock
2029
$126m 268.17%
unlock
2030
$264m 110.06%
unlock
2031
$314m 18.62%
unlock
2032
$334m 6.42%
unlock
2033
$111m 66.69%
unlock

6 RenovoRx Inc Analysts have issued a net profit forecast 2026. The average RenovoRx Inc net profit estimate is

$-12.1m
unlock
. This is
1.71% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-10.0m 19.04%
unlock
, the lowest is
$-13.3m 7.97%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-11.2m 26.79%
2026
$-12.1m 8.15%
unlock
2027
$-6.4m 46.69%
unlock
2028
$1.7m 126.24%
unlock
2029
$40.0m 2,269.23%
unlock
2030
$83.5m 108.62%
unlock
2031
$102m 22.32%
unlock
2032
$101m 0.90%
unlock
2033
$36.4m 64.09%
unlock

Net Margin

2025 -997.32% 95.47%
2026
-305.85% 69.33%
unlock
2027
-55.25% 81.94%
unlock
2028
4.93% 108.92%
unlock
2029
31.80% 545.03%
unlock
2030
31.58% 0.69%
unlock
2031
32.57% 3.13%
unlock
2032
30.33% 6.88%
unlock
2033
32.69% 7.78%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.32 -0.27
20.00% 15.63%
P/E negative
EV/Sales 15.31

6 Analysts have issued a RenovoRx Inc forecast for earnings per share. The average RenovoRx Inc EPS is

$-0.27
unlock
. This is
8.00% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.22 12.00%
unlock
, the lowest is
$-0.29 16.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.32 20.00%
2026
$-0.27 15.63%
unlock
2027
$-0.14 48.15%
unlock
2028
$0.04 128.57%
unlock
2029
$0.89 2,125.00%
unlock
2030
$1.85 107.87%
unlock
2031
$2.26 22.16%
unlock
2032
$2.24 0.88%
unlock
2033
$0.81 63.84%
unlock

P/E ratio

Current -6.20 68.14%
2026
-5.79 6.61%
unlock
2027
-10.85 87.39%
unlock
2028
41.44 481.94%
unlock
2029
1.75 95.78%
unlock
2030
0.84 52.00%
unlock
2031
0.68 19.05%
unlock
2032
0.69 1.47%
unlock
2033
1.92 178.26%
unlock

Based on analysts' sales estimates for 2026, the RenovoRx Inc stock is valued at an EV/Sales of

15.31
unlock
and an P/S ratio of
17.71
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 30.54 74.43%
2026
15.31 49.87%
unlock
2027
5.19 66.13%
unlock
2028
1.77 65.90%
unlock
2029
0.48 72.84%
unlock
2030
0.23 52.40%
unlock
2031
0.19 15.70%
unlock
2032
0.18 6.02%
unlock
2033
0.54 200.22%
unlock

P/S ratio

Current 35.33 80.39%
2026
17.71 49.87%
unlock
2027
6.00 66.13%
unlock
2028
2.05 65.90%
unlock
2029
0.56 72.84%
unlock
2030
0.26 52.39%
unlock
2031
0.22 15.69%
unlock
2032
0.21 6.05%
unlock
2033
0.63 200.19%
unlock

Current RenovoRx Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Ascendiant Capital
Locked
➜
Locked
Locked Aug 28 2026
Ascendiant Capital
Locked
➜
Locked
Locked Jun 01 2026
Ascendiant Capital
Locked
➜
Locked
Locked Apr 09 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Apr 08 2026
Ascendiant Capital
Locked
➜
Locked
Locked Feb 17 2026
Ascendiant Capital
Locked
➜
Locked
Locked Aug 25 2025
Ascendiant Capital
Locked
➜
Locked
Locked Jun 05 2025
Analyst Rating Date
Locked
Ascendiant Capital:
Locked
➜
Locked
Aug 28 2026
Locked
Ascendiant Capital:
Locked
➜
Locked
Jun 01 2026
Locked
Ascendiant Capital:
Locked
➜
Locked
Apr 09 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Apr 08 2026
Locked
Ascendiant Capital:
Locked
➜
Locked
Feb 17 2026
Locked
Ascendiant Capital:
Locked
➜
Locked
Aug 25 2025
Locked
Ascendiant Capital:
Locked
➜
Locked
Jun 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today